nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinolone Acetonide—Wound dehiscence—Carmustine—lymphatic system cancer	0.0728	0.0765	CcSEcCtD
Fluocinolone Acetonide—Wound—Carmustine—lymphatic system cancer	0.0578	0.0608	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Raltitrexed—Methotrexate—lymphatic system cancer	0.0482	1	CbGdCrCtD
Fluocinolone Acetonide—Skin hyperpigmentation—Mechlorethamine—lymphatic system cancer	0.034	0.0357	CcSEcCtD
Fluocinolone Acetonide—Skin striae—Bleomycin—lymphatic system cancer	0.0302	0.0318	CcSEcCtD
Fluocinolone Acetonide—Conjunctival oedema—Carmustine—lymphatic system cancer	0.0302	0.0318	CcSEcCtD
Fluocinolone Acetonide—Skin infection—Mitoxantrone—lymphatic system cancer	0.0258	0.0271	CcSEcCtD
Fluocinolone Acetonide—Retinal haemorrhage—Carmustine—lymphatic system cancer	0.0258	0.0271	CcSEcCtD
Fluocinolone Acetonide—Impaired healing—Carmustine—lymphatic system cancer	0.0194	0.0204	CcSEcCtD
Fluocinolone Acetonide—Fungal skin infection—Mitoxantrone—lymphatic system cancer	0.0187	0.0196	CcSEcCtD
Fluocinolone Acetonide—Telangiectasia—Methotrexate—lymphatic system cancer	0.0165	0.0173	CcSEcCtD
Fluocinolone Acetonide—Skin hyperpigmentation—Bleomycin—lymphatic system cancer	0.0162	0.017	CcSEcCtD
Fluocinolone Acetonide—Skin hyperpigmentation—Carmustine—lymphatic system cancer	0.0141	0.0148	CcSEcCtD
Fluocinolone Acetonide—Taste metallic—Methotrexate—lymphatic system cancer	0.0122	0.0128	CcSEcCtD
Fluocinolone Acetonide—Abscess—Carmustine—lymphatic system cancer	0.0106	0.0111	CcSEcCtD
Fluocinolone Acetonide—Visual disturbance—Fludarabine—lymphatic system cancer	0.01	0.0106	CcSEcCtD
Fluocinolone Acetonide—Wheezing—Bleomycin—lymphatic system cancer	0.00934	0.00981	CcSEcCtD
Fluocinolone Acetonide—Leukoderma—Methotrexate—lymphatic system cancer	0.00914	0.00961	CcSEcCtD
Fluocinolone Acetonide—Impaired healing—Methotrexate—lymphatic system cancer	0.00899	0.00944	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Mechlorethamine—lymphatic system cancer	0.00898	0.00944	CcSEcCtD
Fluocinolone Acetonide—Viral infection—Mitoxantrone—lymphatic system cancer	0.00864	0.00908	CcSEcCtD
Fluocinolone Acetonide—Neck pain—Carmustine—lymphatic system cancer	0.00849	0.00892	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Mechlorethamine—lymphatic system cancer	0.00795	0.00835	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00765	0.00803	CcSEcCtD
Fluocinolone Acetonide—Infection—Mechlorethamine—lymphatic system cancer	0.00717	0.00754	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Fludarabine—lymphatic system cancer	0.00688	0.00723	CcSEcCtD
Fluocinolone Acetonide—Eye pain—Carmustine—lymphatic system cancer	0.00675	0.00709	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Teniposide—lymphatic system cancer	0.00662	0.00696	CcSEcCtD
Fluocinolone Acetonide—Skin hyperpigmentation—Methotrexate—lymphatic system cancer	0.00654	0.00687	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Fludarabine—lymphatic system cancer	0.00635	0.00667	CcSEcCtD
Fluocinolone Acetonide—Folliculitis—Methotrexate—lymphatic system cancer	0.00618	0.0065	CcSEcCtD
Fluocinolone Acetonide—Diplopia—Carmustine—lymphatic system cancer	0.00609	0.0064	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Fludarabine—lymphatic system cancer	0.00582	0.00611	CcSEcCtD
Fluocinolone Acetonide—Pain in extremity—Vincristine—lymphatic system cancer	0.00582	0.00611	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Fludarabine—lymphatic system cancer	0.00573	0.00602	CcSEcCtD
Fluocinolone Acetonide—Oedema—Teniposide—lymphatic system cancer	0.00532	0.00559	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00532	0.00559	CcSEcCtD
Fluocinolone Acetonide—Infection—Teniposide—lymphatic system cancer	0.00529	0.00556	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Mechlorethamine—lymphatic system cancer	0.00511	0.00537	CcSEcCtD
Fluocinolone Acetonide—Cough—Fludarabine—lymphatic system cancer	0.005	0.00526	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00494	0.00519	CcSEcCtD
Fluocinolone Acetonide—Abscess—Methotrexate—lymphatic system cancer	0.00491	0.00516	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Fludarabine—lymphatic system cancer	0.00488	0.00513	CcSEcCtD
Fluocinolone Acetonide—Oedema—Fludarabine—lymphatic system cancer	0.00468	0.00492	CcSEcCtD
Fluocinolone Acetonide—Infection—Fludarabine—lymphatic system cancer	0.00465	0.00488	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00459	0.00482	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00459	0.00482	CcSEcCtD
Fluocinolone Acetonide—Rash—Mechlorethamine—lymphatic system cancer	0.00455	0.00478	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00455	0.00478	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00455	0.00478	CcSEcCtD
Fluocinolone Acetonide—Nausea—Mechlorethamine—lymphatic system cancer	0.00429	0.00451	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Bleomycin—lymphatic system cancer	0.00427	0.00448	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00426	0.00448	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Methotrexate—lymphatic system cancer	0.00422	0.00443	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Teniposide—lymphatic system cancer	0.00421	0.00442	CcSEcCtD
Fluocinolone Acetonide—Erythema—Bleomycin—lymphatic system cancer	0.0042	0.00442	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00414	0.00435	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00409	0.0043	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Carmustine—lymphatic system cancer	0.00406	0.00427	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00404	0.00424	CcSEcCtD
Fluocinolone Acetonide—Pain—Fludarabine—lymphatic system cancer	0.004	0.0042	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00395	0.00415	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Carmustine—lymphatic system cancer	0.00394	0.00414	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00393	0.00413	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Teniposide—lymphatic system cancer	0.00392	0.00412	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Teniposide—lymphatic system cancer	0.00377	0.00396	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Carmustine—lymphatic system cancer	0.00372	0.00391	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Fludarabine—lymphatic system cancer	0.0037	0.00389	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Carmustine—lymphatic system cancer	0.00369	0.00388	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Carmustine—lymphatic system cancer	0.00367	0.00385	CcSEcCtD
Fluocinolone Acetonide—Erythema—Carmustine—lymphatic system cancer	0.00367	0.00385	CcSEcCtD
Fluocinolone Acetonide—Cough—Bleomycin—lymphatic system cancer	0.00367	0.00385	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Teniposide—lymphatic system cancer	0.00364	0.00383	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00363	0.00381	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Vincristine—lymphatic system cancer	0.00356	0.00374	CcSEcCtD
Fluocinolone Acetonide—Back pain—Carmustine—lymphatic system cancer	0.00355	0.00373	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Vincristine—lymphatic system cancer	0.00352	0.0037	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Mitoxantrone—lymphatic system cancer	0.00346	0.00364	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Carmustine—lymphatic system cancer	0.00346	0.00363	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00345	0.00362	CcSEcCtD
Fluocinolone Acetonide—Oedema—Bleomycin—lymphatic system cancer	0.00343	0.0036	CcSEcCtD
Fluocinolone Acetonide—Erythema—Mitoxantrone—lymphatic system cancer	0.00341	0.00358	CcSEcCtD
Fluocinolone Acetonide—Infection—Bleomycin—lymphatic system cancer	0.00341	0.00358	CcSEcCtD
Fluocinolone Acetonide—Back pain—Vincristine—lymphatic system cancer	0.00339	0.00356	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Teniposide—lymphatic system cancer	0.00338	0.00356	CcSEcCtD
Fluocinolone Acetonide—Rash—Teniposide—lymphatic system cancer	0.00336	0.00353	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Teniposide—lymphatic system cancer	0.00335	0.00352	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00334	0.00351	CcSEcCtD
Fluocinolone Acetonide—Headache—Teniposide—lymphatic system cancer	0.00333	0.0035	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Fludarabine—lymphatic system cancer	0.00331	0.00348	CcSEcCtD
Fluocinolone Acetonide—Back pain—Mitoxantrone—lymphatic system cancer	0.0033	0.00347	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00321	0.00338	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Fludarabine—lymphatic system cancer	0.0032	0.00336	CcSEcCtD
Fluocinolone Acetonide—Nausea—Teniposide—lymphatic system cancer	0.00316	0.00332	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Vincristine—lymphatic system cancer	0.00315	0.00331	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00313	0.00328	CcSEcCtD
Fluocinolone Acetonide—Oedema—Carmustine—lymphatic system cancer	0.00299	0.00315	CcSEcCtD
Fluocinolone Acetonide—Visual disturbance—Methotrexate—lymphatic system cancer	0.00298	0.00313	CcSEcCtD
Fluocinolone Acetonide—Cough—Mitoxantrone—lymphatic system cancer	0.00298	0.00313	CcSEcCtD
Fluocinolone Acetonide—Infection—Carmustine—lymphatic system cancer	0.00297	0.00313	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Fludarabine—lymphatic system cancer	0.00297	0.00313	CcSEcCtD
Fluocinolone Acetonide—Rash—Fludarabine—lymphatic system cancer	0.00295	0.0031	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Fludarabine—lymphatic system cancer	0.00295	0.0031	CcSEcCtD
Fluocinolone Acetonide—Pain—Bleomycin—lymphatic system cancer	0.00293	0.00308	CcSEcCtD
Fluocinolone Acetonide—Headache—Fludarabine—lymphatic system cancer	0.00293	0.00308	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.0029	0.00305	CcSEcCtD
Fluocinolone Acetonide—Oedema—Vincristine—lymphatic system cancer	0.00286	0.003	CcSEcCtD
Fluocinolone Acetonide—Infection—Vincristine—lymphatic system cancer	0.00284	0.00298	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Vincristine—lymphatic system cancer	0.0028	0.00295	CcSEcCtD
Fluocinolone Acetonide—Oedema—Mitoxantrone—lymphatic system cancer	0.00278	0.00292	CcSEcCtD
Fluocinolone Acetonide—Nausea—Fludarabine—lymphatic system cancer	0.00278	0.00292	CcSEcCtD
Fluocinolone Acetonide—Infection—Mitoxantrone—lymphatic system cancer	0.00277	0.00291	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00273	0.00287	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Bleomycin—lymphatic system cancer	0.00271	0.00285	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.0026	0.00274	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00259	0.00272	CcSEcCtD
Fluocinolone Acetonide—Pain—Carmustine—lymphatic system cancer	0.00256	0.00269	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00254	0.00266	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00253	0.00266	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00247	0.00259	CcSEcCtD
Fluocinolone Acetonide—Pain—Vincristine—lymphatic system cancer	0.00244	0.00257	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Bleomycin—lymphatic system cancer	0.00243	0.00255	CcSEcCtD
Fluocinolone Acetonide—Pain—Mitoxantrone—lymphatic system cancer	0.00238	0.0025	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Carmustine—lymphatic system cancer	0.00237	0.00249	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00227	0.00238	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Vincristine—lymphatic system cancer	0.00226	0.00237	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Carmustine—lymphatic system cancer	0.00221	0.00232	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.0022	0.00231	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Bleomycin—lymphatic system cancer	0.00218	0.00229	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Methotrexate—lymphatic system cancer	0.00217	0.00228	CcSEcCtD
Fluocinolone Acetonide—Infestation—Methotrexate—lymphatic system cancer	0.00217	0.00228	CcSEcCtD
Fluocinolone Acetonide—Rash—Bleomycin—lymphatic system cancer	0.00216	0.00227	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Bleomycin—lymphatic system cancer	0.00216	0.00227	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Vincristine—lymphatic system cancer	0.00211	0.00221	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00205	0.00215	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Carmustine—lymphatic system cancer	0.00205	0.00215	CcSEcCtD
Fluocinolone Acetonide—Nausea—Bleomycin—lymphatic system cancer	0.00204	0.00214	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Carmustine—lymphatic system cancer	0.00198	0.00208	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Vincristine—lymphatic system cancer	0.00196	0.00205	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.0019	0.002	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Carmustine—lymphatic system cancer	0.0019	0.002	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Vincristine—lymphatic system cancer	0.00189	0.00199	CcSEcCtD
Fluocinolone Acetonide—Rash—Carmustine—lymphatic system cancer	0.00189	0.00198	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Carmustine—lymphatic system cancer	0.00189	0.00198	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Methotrexate—lymphatic system cancer	0.00188	0.00198	CcSEcCtD
Fluocinolone Acetonide—Headache—Carmustine—lymphatic system cancer	0.00188	0.00197	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Methotrexate—lymphatic system cancer	0.00182	0.00192	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Vincristine—lymphatic system cancer	0.00182	0.00191	CcSEcCtD
Fluocinolone Acetonide—Rash—Vincristine—lymphatic system cancer	0.0018	0.00189	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Vincristine—lymphatic system cancer	0.0018	0.00189	CcSEcCtD
Fluocinolone Acetonide—Headache—Vincristine—lymphatic system cancer	0.00179	0.00188	CcSEcCtD
Fluocinolone Acetonide—Nausea—Carmustine—lymphatic system cancer	0.00178	0.00187	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00177	0.00186	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00176	0.00185	CcSEcCtD
Fluocinolone Acetonide—Rash—Mitoxantrone—lymphatic system cancer	0.00176	0.00184	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00175	0.00184	CcSEcCtD
Fluocinolone Acetonide—Headache—Mitoxantrone—lymphatic system cancer	0.00174	0.00183	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Methotrexate—lymphatic system cancer	0.00173	0.00181	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Methotrexate—lymphatic system cancer	0.00171	0.0018	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Methotrexate—lymphatic system cancer	0.0017	0.00179	CcSEcCtD
Fluocinolone Acetonide—Erythema—Methotrexate—lymphatic system cancer	0.0017	0.00179	CcSEcCtD
Fluocinolone Acetonide—Nausea—Vincristine—lymphatic system cancer	0.0017	0.00178	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Methotrexate—lymphatic system cancer	0.00166	0.00175	CcSEcCtD
Fluocinolone Acetonide—Nausea—Mitoxantrone—lymphatic system cancer	0.00165	0.00174	CcSEcCtD
Fluocinolone Acetonide—Back pain—Methotrexate—lymphatic system cancer	0.00164	0.00173	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Methotrexate—lymphatic system cancer	0.0016	0.00168	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Methotrexate—lymphatic system cancer	0.00153	0.0016	CcSEcCtD
Fluocinolone Acetonide—Cough—Methotrexate—lymphatic system cancer	0.00148	0.00156	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Methotrexate—lymphatic system cancer	0.00145	0.00152	CcSEcCtD
Fluocinolone Acetonide—Infection—Methotrexate—lymphatic system cancer	0.00138	0.00145	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00136	0.00143	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00126	0.00133	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.0012	0.00126	CcSEcCtD
Fluocinolone Acetonide—Pain—Methotrexate—lymphatic system cancer	0.00119	0.00125	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Methotrexate—lymphatic system cancer	0.0011	0.00115	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00102	0.00107	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Methotrexate—lymphatic system cancer	0.000981	0.00103	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000949	0.000997	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Methotrexate—lymphatic system cancer	0.000917	0.000964	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Methotrexate—lymphatic system cancer	0.000882	0.000926	CcSEcCtD
Fluocinolone Acetonide—Rash—Methotrexate—lymphatic system cancer	0.000874	0.000919	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Methotrexate—lymphatic system cancer	0.000874	0.000918	CcSEcCtD
Fluocinolone Acetonide—Headache—Methotrexate—lymphatic system cancer	0.000869	0.000913	CcSEcCtD
Fluocinolone Acetonide—Nausea—Methotrexate—lymphatic system cancer	0.000824	0.000866	CcSEcCtD
